VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors

All categories

DBCAT005990Pharmacologic classL01FG

A DrugBank category of 2 drugs. 2 of them are approved.

ATC classification: L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 — ANTINEOPLASTIC AGENTS
L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01FG — VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors
Drugs: Bevacizumab
Ramucirumab

What you can answer from here — as of May 01, 2025

2DrugsEach linked to its full drug card

Listed above

10Drug targetsEvery drug–target pair in the class, with bond type

157Marketed productsAcross the regions we cover, with dosage forms and routes

4Routes of administrationHow the drugs in this class are given

Which targets do VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account